The effectiveness of extracorporeal shock wave therapy on breast cancer-related lymphedema: A literature review.
breast cancer
extracorporeal shock wave therapy
lymphedema
physical medicine and rehabilitation
Journal
Lymphology
ISSN: 2522-7963
Titre abrégé: Lymphology
Pays: United States
ID NLM: 0155112
Informations de publication
Date de publication:
2020
2020
Historique:
entrez:
22
12
2020
pubmed:
23
12
2020
medline:
7
10
2021
Statut:
ppublish
Résumé
Lymphedema is one of the most dreaded complications related to breast cancer surgery, commonly resulting in upper limb functional, esthetic, and psychological impairment. The necessity to improve the efficacy of conventional treatments and the promising effect of extracorporeal shock wave therapy (ESWT) on lymphangiogenesis in vitro and animal models, has prompted studies involving women affected by breast cancer-related lymphedema. Since intervention modalities and treatment protocols used are different, a review is necessary to verify the effectiveness of ESWT, evaluating the quality of existing studies and the eventual need for further research. Data were obtained from PubMed, Scopus, Google Scholar, Cochrane Library and PEDro, including articles published until January 2019. Five studies met the inclusion criteria. Evident heterogeneity emerged among selected studies permitting only a purely descriptive analysis of their data and strongly limiting their comparison. When compared to other treatment modalities, ESWT showed a significant effect on measured outcomes. It is clear that further high quality research is necessary to assert with confidence the effects and possible superiority of ESWT over other conservative therapies in the management of breast cancer-related lymphedema.
Types de publication
Journal Article
Meta-Analysis
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
118-135Informations de copyright
Copyright by International Society of Lymphology.
Déclaration de conflit d'intérêts
The authors of this article and the planning committee members and staff have no relevant financial relationships with commercial interests to disclose.